# Pierfrancesco Tassone

## List of Publications by Citations



| | | | |
|---|---|---|---|
| 281 papers | 12,625 citations | 63 h-index | 99 g-index |
| 289 ext. papers | 14,182 ext. citations | 5.7 avg, IF | 5.85 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 281 | Mir-34: a new weapon against cancer?. *Molecular Therapy - Nucleic Acids*, **2014**, 3, e194 | 10.7 | 358 |
| 280 | Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncology, The*, **2016**, 17, 367-377 | 21.7 | 339 |
| 279 | Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. *Blood*, **2009**, 114, 371-9 | 2.2 | 331 |
| 278 | Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncology, The*, **2017**, 18, 1688-1700 | 21.7 | 328 |
| 277 | Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. *Blood*, **2006**, 108, 3441-9 | 2.2 | 300 |
| 276 | BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. *British Journal of Cancer*, **2003**, 88, 1285-91 | 8.7 | 298 |
| 275 | HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. *Blood*, **2005**, 105, 251-8 | 2.2 | 253 |
| 274 | Evidence of a founder mutation of BRCA1 in a highly homogeneous population from southern Italy with breast/ovarian cancer. *Human Mutation*, **2001**, 18, 163-4 | 4.7 | 206 |
| 273 | Dysfunctional T regulatory cells in multiple myeloma. *Blood*, **2006**, 107, 301-4 | 2.2 | 188 |
| 272 | Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. *Clinical Cancer Research*, **2012**, 18, 6260-70 | 12.9 | 185 |
| 271 | Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy. *Journal of Immunotherapy*, **2010**, 33, 435-41 | 5 | 173 |
| 270 | Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth. *Clinical Cancer Research* , **2013**, 19, 2096-106 | 12.9 | 165 |
| 269 | MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches. *Journal of Hematology and Oncology*, **2018**, 11, 63 | 22.4 | 160 |
| 268 | Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). *Blood*, **2007**, 109, 1220-7 | 2.2 | 140 |
| 267 | In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells. *Cancer Research*, **2004**, 64, 4629-36 | 10.1 | 139 |
| 266 | miR-29b negatively regulates human osteoclastic cell differentiation and function: implications for the treatment of multiple myeloma-related bone disease. *Journal of Cellular Physiology*, **2013**, 228, 1506-15 | 7 | 138 |
| 265 | Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. *Leukemia*, **2018**, 32, 1948-1957 | 10.7 | 129 |

| | | | |
|---|---|---|---|
| 264 | Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. *Leukemia*, **2000**, 14, 841-4 | 10.7 | 128 |
| 263 | Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. *British Journal of Cancer*, **2003**, 88, 1971-8 | 8.7 | 127 |
| 262 | DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma. *Oncotarget*, **2012**, 3, 1246-58 | 3.3 | 127 |
| 261 | Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation. *Oncotarget*, **2015**, 6, 13772-89 | 3.3 | 124 |
| 260 | miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1. *Cell Death and Disease*, **2012**, 3, e436 | 9.8 | 122 |
| 259 | MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. *Clinical Cancer Research*, **2006**, 12, 5887-94 | 12.9 | 118 |
| 258 | Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. *Clinical Cancer Research*, **2007**, 13, 5903-9 | 12.9 | 116 |
| 257 | Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. *Blood*, **2004**, 104, 3688-96 | 2.2 | 111 |
| 256 | A clinically relevant SCID-hu in vivo model of human multiple myeloma. *Blood*, **2005**, 106, 713-6 | 2.2 | 109 |
| 255 | In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma. *Oncotarget*, **2013**, 4, 242-55 | 3.3 | 109 |
| 254 | Integrin 7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion. *Blood*, **2011**, 117, 6202-13 | 2.2 | 104 |
| 253 | Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. *Blood*, **2007**, 110, 1656-63 | 2.2 | 103 |
| 252 | A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. *Clinical Cancer Research*, **2009**, 15, 7144-52 | 12.9 | 98 |
| 251 | Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors. *Blood*, **2011**, 118, 6368-79 | 2.2 | 95 |
| 250 | miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies. *Oncotarget*, **2015**, 6, 12837-61 | 3.3 | 95 |
| 249 | Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma. *Blood*, **2012**, 120, 5002-13 | 2.2 | 94 |
| 248 | A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells. *Leukemia*, **2011**, 25, 707-11 | 10.7 | 91 |
| 247 | Delivery of miR-34a by chitosan/PLGA nanoplexes for the anticancer treatment of multiple myeloma. *Scientific Reports*, **2015**, 5, 17579 | 4.9 | 90 |

| | | | |
|---|---|---|---|
| 246 | Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib. *British Journal of Haematology*, **2006**, 134, 145-56 | 4.5 | 90 |
| 245 | In vivo activity of miR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma. *PLoS ONE*, **2014**, 9, e90005 | 3.7 | 90 |
| 244 | Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials. *European Journal of Cancer*, **2013**, 49, 593-603 | 7.5 | 89 |
| 243 | Epigenetic inactivation of RUNX3 in microsatellite unstable sporadic colon cancers. *International Journal of Cancer*, **2004**, 112, 754-9 | 7.5 | 89 |
| 242 | Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes. *Nanomedicine: Nanotechnology, Biology, and Medicine*, **2011**, 7, 955-64 | 6 | 88 |
| 241 | Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma. *Clinical Cancer Research*, **2005**, 11, 4251-8 | 12.9 | 88 |
| 240 | Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo. *Leukemia*, **2015**, 29, 2173-83 | 10.7 | 86 |
| 239 | miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells. *Cell Cycle*, **2013**, 12, 3650-62 | 4.7 | 86 |
| 238 | Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib. *Blood*, **2008**, 112, 1346-56 | 2.2 | 86 |
| 237 | Promises and challenges of MicroRNA-based treatment of multiple myeloma. *Current Cancer Drug Targets*, **2012**, 12, 838-46 | 2.8 | 80 |
| 236 | Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo. *Leukemia*, **2008**, 22, 1410-8 | 10.7 | 80 |
| 235 | Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity. *Oncotarget*, **2014**, 5, 3039-54 | 3.3 | 80 |
| 234 | A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells. *Clinical Cancer Research*, **2016**, 22, 1222-33 | 12.9 | 79 |
| 233 | Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts. *Oncotarget*, **2015**, 6, 27343-58 | 3.3 | 78 |
| 232 | Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo. *Cancer Biology and Therapy*, **2009**, 8, 648-53 | 4.6 | 78 |
| 231 | A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells. *Journal of Cellular Physiology*, **2014**, 229, 2106-16 | 7 | 76 |
| 230 | Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia. *Clinical Cancer Research*, **2013**, 19, 3130-42 | 12.9 | 76 |
| 229 | NF-kappaB/Rel-mediated regulation of apoptosis in hematologic malignancies and normal hematopoietic progenitors. *Leukemia*, **2004**, 18, 11-7 | 10.7 | 76 |

| | | | |
|---|---|---|---|
| 228 | Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients. *Cancer Biology and Therapy*, **2013**, 14, 469-75 | 4.6 | 75 |
| 227 | Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma. *Molecular Cancer Therapeutics*, **2016**, 15, 1364-75 | 6.1 | 75 |
| 226 | New pharmacokinetic and pharmacodynamic tools for interferon-alpha (IFN-alpha) treatment of human cancer. *Cancer Immunology, Immunotherapy*, **2005**, 54, 1-10 | 7.4 | 74 |
| 225 | Aberrant glycosylation as biomarker for cancer: focus on CD43. *BioMed Research International*, **2014** , 2014, 742831 | 3 | 72 |
| 224 | In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells. *PLoS ONE*, **2014**, 9, e89659 | 3.7 | 72 |
| 223 | The farnesyl transferase inhibitor R115777 (Zarnestra) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and Pamidronate. *Oncogene*, **2004**, 23, 6900-13 | 9.2 | 69 |
| 222 | A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer. *British Journal of Cancer*, **2014**, 111, 660-6 | 8.7 | 68 |
| 221 | Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: a DMET microarray profiling study. *Cancer Biology and Therapy*, **2011**, 12, 780-7 | 4.6 | 67 |
| 220 | Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial. *Lancet Respiratory Medicine,the*, **2020**, 8, 1132-1143 | 35.1 | 66 |
| 219 | Non-coding RNA: a novel opportunity for the personalized treatment of multiple myeloma. *Expert Opinion on Biological Therapy*, **2013**, 13 Suppl 1, S125-37 | 5.4 | 65 |
| 218 | Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial). *Clinical Cancer Research*, **2008**, 14, 4192-9 | 12.9 | 63 |
| 217 | Protein kinase CK2 protects multiple myeloma cells from ER stress-induced apoptosis and from the cytotoxic effect of HSP90 inhibition through regulation of the unfolded protein response. *Clinical Cancer Research*, **2012**, 18, 1888-900 | 12.9 | 61 |
| 216 | EGF activates an inducible survival response via the RAS-> Erk-1/2 pathway to counteract interferon-alpha-mediated apoptosis in epidermoid cancer cells. *Cell Death and Differentiation*, **2003**, 10, 218-29 | 12.7 | 61 |
| 215 | The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells. *Nature Medicine*, **2015**, 21, 572-80 | 50.5 | 60 |
| 214 | Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma. *Molecular Cancer Therapeutics*, **2016**, 15, 1364-1375 | 6.1 | 60 |
| 213 | A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling. *British Journal of Haematology*, **2011**, 154, 529-33 | 4.5 | 58 |
| 212 | In vivo activity of gemcitabine-loaded PEGylated small unilamellar liposomes against pancreatic cancer. *Cancer Chemotherapy and Pharmacology*, **2009**, 64, 1009-20 | 3.5 | 58 |
| 211 | Tumor infiltration by T lymphocytes expressing chemokine receptor 7 (CCR7) is predictive of favorable outcome in patients with advanced colorectal carcinoma. *Clinical Cancer Research*, **2012**, 18, 850-7 | 12.9 | 58 |

| | | | |
|---|---|---|---|
| 210 | The eukaryotic initiation factor 5A is involved in the regulation of proliferation and apoptosis induced by interferon-alpha and EGF in human cancer cells. *Journal of Biochemistry*, **2003**, 133, 757-65 | 3.1 | 57 |
| 209 | Non-coding RNAs in cancer: platforms and strategies for investigating the genomic "dark matter". *Journal of Experimental and Clinical Cancer Research*, **2020**, 39, 117 | 12.8 | 56 |
| 208 | Molecular targets for the treatment of multiple myeloma. *Current Cancer Drug Targets*, **2012**, 12, 757-67 | 2.8 | 56 |
| 207 | The expression pattern of small nucleolar and small Cajal body-specific RNAs characterizes distinct molecular subtypes of multiple myeloma. *Blood Cancer Journal*, **2012**, 2, e96 | 7 | 55 |
| 206 | Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC). *European Journal of Cancer*, **2010**, 46, 1703-11 | 7.5 | 55 |
| 205 | Small nucleolar RNAs as new biomarkers in chronic lymphocytic leukemia. *BMC Medical Genomics*, **2013**, 6, 27 | 3.7 | 54 |
| 204 | Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo. *Blood*, **2005**, 105, 4470-6 | 2.2 | 54 |
| 203 | In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor. *British Journal of Haematology*, **2008**, 143, 520-31 | 4.5 | 53 |
| 202 | Establishment of BCWM.1 cell line for Waldenstrm's macroglobulinemia with productive in vivo engraftment in SCID-hu mice. *Experimental Hematology*, **2007**, 35, 1366-75 | 3.1 | 53 |
| 201 | DMET-analyzer: automatic analysis of Affymetrix DMET data. *BMC Bioinformatics*, **2012**, 13, 258 | 3.6 | 52 |
| 200 | SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. *Blood*, **2005**, 106, 706-12 | 2.2 | 52 |
| 199 | Epstein-Barr virus nuclear antigen 2 transactivates the long terminal repeat of human immunodeficiency virus type 1. *Journal of Virology*, **1993**, 67, 2853-61 | 6.6 | 52 |
| 198 | Clinical monoclonal B lymphocytosis versus Rai 0 chronic lymphocytic leukemia: A comparison of cellular, cytogenetic, molecular, and clinical features. *Clinical Cancer Research*, **2013**, 19, 5890-900 | 12.9 | 50 |
| 197 | Myeloid-derived suppressor cells in multiple myeloma: pre-clinical research and translational opportunities. *Frontiers in Oncology*, **2014**, 4, 348 | 5.3 | 48 |
| 196 | Epigenetic modifications in multiple myeloma: recent advances on the role of DNA and histone methylation. *Expert Opinion on Therapeutic Targets*, **2017**, 21, 91-101 | 6.4 | 47 |
| 195 | Nanoparticle albumin bound Paclitaxel in the treatment of human cancer: nanodelivery reaches prime-time?. *Journal of Drug Delivery*, **2013**, 2013, 905091 | 2.3 | 47 |
| 194 | DMET (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine. *Oncotarget*, **2016**, 7, 54028-54050 | 3.3 | 47 |
| 193 | Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo. *Molecular Cancer Therapeutics*, **2009**, 8, 26-35 | 6.1 | 46 |

| | | | |
|---|---|---|---|
| 192 | p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications. *British Journal of Haematology*, **2008**, 141, 598-606 | 4.5 | 46 |
| 191 | Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma. *Oncotarget*, **2017**, 8, 106527-106537 | 3.3 | 46 |
| 190 | Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma. *Leukemia*, **2020**, 34, 234-244 | 10.7 | 46 |
| 189 | Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma. *Leukemia*, **2018**, 32, 996-1002 | 10.7 | 45 |
| 188 | miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth. *Blood Cancer Journal*, **2016**, 6, e380 | 7 | 44 |
| 187 | Significant biological role of sp1 transactivation in multiple myeloma. *Clinical Cancer Research*, **2011**, 17, 6500-9 | 12.9 | 44 |
| 186 | Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients. *Blood Advances*, **2017**, 1, 455-466 | 7.8 | 43 |
| 185 | MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment. *BioMed Research International*, **2016**, 2016, 6504593 | 3 | 42 |
| 184 | microRNAome expression in chronic lymphocytic leukemia: comparison with normal B-cell subsets and correlations with prognostic and clinical parameters. *Clinical Cancer Research*, **2014**, 20, 4141-53 | 12.9 | 41 |
| 183 | Pegylated liposomal doxorubicin in the management of ovarian cancer: a systematic review and metaanalysis of randomized trials. *Cancer Biology and Therapy*, **2014**, 15, 707-20 | 4.6 | 41 |
| 182 | Mouse models as a translational platform for the development of new therapeutic agents in multiple myeloma. *Current Cancer Drug Targets*, **2012**, 12, 814-22 | 2.8 | 41 |
| 181 | Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives. *Critical Reviews in Oncology/Hematology*, **2019**, 140, 67-72 | 7 | 40 |
| 180 | Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92. *Blood*, **2018**, 132, 1050-1063 | 2.2 | 40 |
| 179 | Transcriptional characterization of a prospective series of primary plasma cell leukemia revealed signatures associated with tumor progression and poorer outcome. *Clinical Cancer Research*, **2013**, 19, 3247-58 | 12.9 | 40 |
| 178 | Role of systemic chemotherapy in the management of resected or resectable colorectal liver metastases: a systematic review and meta-analysis of randomized controlled trials. *Oncology Reports*, **2012**, 27, 1849-56 | 3.5 | 40 |
| 177 | MicroRNAs in the pathobiology of multiple myeloma. *Current Cancer Drug Targets*, **2012**, 12, 823-37 | 2.8 | 40 |
| 176 | MicroRNA and multiple myeloma: from laboratory findings to translational therapeutic approaches. *Current Pharmaceutical Biotechnology*, **2014**, 15, 459-67 | 2.6 | 40 |
| 175 | Enhancement of cytosine arabinoside-induced apoptosis in human myeloblastic leukemia cells by NF-kappa B/Rel- specific decoy oligodeoxynucleotides. *Gene Therapy*, **2000**, 7, 1234-7 | 4 | 39 |

| | | | |
|---|---|---|---|
| 174 | From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario. *Current Drug Targets*, **2013**, 14, 1144-9 | 3 | 39 |
| 173 | Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse. *Cancer Biology and Therapy*, **2016**, 17, 1213-1220 | 4.6 | 38 |
| 172 | The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment. *Leukemia*, **2017**, 31, 1570-1581 | 10.7 | 38 |
| 171 | Transferrin-conjugated SNALPs encapsulating 2'-O-methylated miR-34a for the treatment of multiple myeloma. *BioMed Research International*, **2014**, 2014, 217365 | 3 | 38 |
| 170 | Integrated analysis of microRNAs, transcription factors and target genes expression discloses a specific molecular architecture of hyperdiploid multiple myeloma. *Oncotarget*, **2015**, 6, 19132-47 | 3.3 | 37 |
| 169 | Mir-221/222 are promising targets for innovative anticancer therapy. *Expert Opinion on Therapeutic Targets*, **2016**, 20, 1099-108 | 6.4 | 36 |
| 168 | MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells. *Leukemia*, **2018**, 32, 1003-1015 | 10.7 | 36 |
| 167 | Bergamot Polyphenols Improve Dyslipidemia and Pathophysiological Features in a Mouse Model of Non-Alcoholic Fatty Liver Disease. *Scientific Reports*, **2020**, 10, 2565 | 4.9 | 35 |
| 166 | Pharmacokinetics and Pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in Mice and Non-human Primates. *Molecular Therapy - Nucleic Acids*, **2016**, 5, | 10.7 | 35 |
| 165 | Immunologic microenvironment and personalized treatment in multiple myeloma. *Expert Opinion on Biological Therapy*, **2013**, 13 Suppl 1, S83-93 | 5.4 | 35 |
| 164 | A SCID-hu in vivo model of human Waldenstrm macroglobulinemia. *Blood*, **2005**, 106, 1341-5 | 2.2 | 35 |
| 163 | Disentangling the microRNA regulatory milieu in multiple myeloma: integrative genomics analysis outlines mixed miRNA-TF circuits and pathway-derived networks modulated in t(4;14) patients. *Oncotarget*, **2016**, 7, 2367-78 | 3.3 | 35 |
| 162 | Physicochemical features and transfection properties of chitosan/poloxamer 188/poly(D,L-lactide-co-glycolide) nanoplexes. *International Journal of Nanomedicine*, **2014**, 9, 2359-72 | 7.3 | 34 |
| 161 | Sphingosine analog fingolimod (FTY720) increases radiation sensitivity of human breast cancer cells in vitro. *Cancer Biology and Therapy*, **2014**, 15, 797-805 | 4.6 | 34 |
| 160 | Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: the GOLFIG-2 multicentric open-label randomized phase III trial. *Journal of Immunotherapy* , **2014**, 37, 26-35 | 5 | 34 |
| 159 | Emerging pathways as individualized therapeutic target of multiple myeloma. *Expert Opinion on Biological Therapy*, **2013**, 13 Suppl 1, S95-109 | 5.4 | 34 |
| 158 | Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis. *Cancer Chemotherapy and Pharmacology*, **2016**, 77, 205-9 | 3.5 | 33 |
| 157 | miR-221 stimulates breast cancer cells and cancer-associated fibroblasts (CAFs) through selective interference with the A20/c-Rel/CTGF signaling. *Journal of Experimental and Clinical Cancer Research*, **2018**, 37, 94 | 12.8 | 33 |

| | | | |
|---|---|---|---|
| 156 | Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment. *Scientific Reports*, **2017**, 7, 17949 | 4.9 | 33 |
| 155 | The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines. *Leukemia and Lymphoma*, **2008**, 49, 1374-83 | 1.9 | 33 |
| 154 | lncRNA profiling in early-stage chronic lymphocytic leukemia identifies transcriptional fingerprints with relevance in clinical outcome. *Blood Cancer Journal*, **2016**, 6, e468 | 7 | 33 |
| 153 | Cutting the limits of aminobisphosphonates: new strategies for the potentiation of their anti-tumour effects. *Current Cancer Drug Targets*, **2009**, 9, 791-800 | 2.8 | 32 |
| 152 | Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance. *Blood*, **2009**, 114, 3276-84 | 2.2 | 31 |
| 151 | Immune-modulating effects of the newest cetuximab-based chemoimmunotherapy regimen in advanced colorectal cancer patients. *Journal of Immunotherapy*, **2012**, 35, 440-7 | 5 | 30 |
| 150 | A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias. *Oncotarget*, **2015**, 6, 26129-41 | 3.3 | 30 |
| 149 | A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival. *Blood Cancer Journal*, **2016**, 6, e511 | 7 | 30 |
| 148 | miR-22 suppresses DNA ligase III addiction in multiple myeloma. *Leukemia*, **2019**, 33, 487-498 | 10.7 | 29 |
| 147 | Synergistic induction of growth arrest and apoptosis of human myeloma cells by the IL-6 super-antagonist Sant7 and Dexamethasone. *Cell Death and Differentiation*, **2000**, 7, 327-8 | 12.7 | 29 |
| 146 | Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients. *Journal of Ovarian Research*, **2016**, 9, 31 | 5.5 | 29 |
| 145 | The Era of PARP inhibitors in ovarian cancer: "Class Action" or not? A systematic review and meta-analysis. *Critical Reviews in Oncology/Hematology*, **2018**, 131, 83-89 | 7 | 29 |
| 144 | Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma. *Cancer Research*, **2004**, 64, 8746-53 | 10.1 | 28 |
| 143 | Circulating biomarkers in osteosarcoma: new translational tools for diagnosis and treatment. *Oncotarget*, **2017**, 8, 100831-100851 | 3.3 | 28 |
| 142 | Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients. *Cancer Biology and Therapy*, **2010**, 9, 685-93 | 4.6 | 27 |
| 141 | Tumor infiltration by chemokine receptor 7 (CCR7)(+) T-lymphocytes is a favorable prognostic factor in metastatic colorectal cancer. *OncoImmunology*, **2012**, 1, 531-532 | 7.2 | 26 |
| 140 | Radiomics predicts survival of patients with advanced non-small cell lung cancer undergoing PD-1 blockade using Nivolumab. *Oncology Letters*, **2020**, 19, 1559-1566 | 2.6 | 26 |
| 139 | A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate?. *Cancer Biology and Therapy*, **2015**, 16, 1148-59 | 4.6 | 25 |

| | | | |
|---|---|---|---|
| 138 | Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma. *Cancers* , **2019**, 11, | 6.6 | 25 |
| 137 | Genetics and molecular profiling of multiple myeloma: novel tools for clinical management?. *European Journal of Cancer*, **2006**, 42, 1530-8 | 7.5 | 25 |
| 136 | Mouse models of multiple myeloma: technologic platforms and perspectives. *Oncotarget*, **2018**, 9, 20119-20133 | 5.3 | 24 |
| 135 | Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: implication for therapy. *Leukemia*, **2017**, 31, 1894-1904 | 10.7 | 23 |
| 134 | Evidence of shared epitopic reactivity among independent B-cell clones in chronic lymphocytic leukemia patients. *Leukemia*, **2016**, 30, 2419-2422 | 10.7 | 22 |
| 133 | Biological pathways and in vivo antitumor activity induced by Atiprimod in myeloma. *Leukemia*, **2007**, 21, 2519-26 | 10.7 | 22 |
| 132 | Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma. *Cancers*, **2019**, 11, | 6.6 | 22 |
| 131 | miR-125b Upregulates miR-34a and Sequentially Activates Stress Adaption and Cell Death Mechanisms in Multiple Myeloma. *Molecular Therapy - Nucleic Acids*, **2019**, 16, 391-406 | 10.7 | 21 |
| 130 | Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorectal cancer patients. *OncoImmunology*, **2016**, 5, e1101205 | 7.2 | 21 |
| 129 | miRNAs and lncRNAs as Novel Therapeutic Targets to Improve Cancer Immunotherapy. *Cancers*, **2021**, 13, | 6.6 | 21 |
| 128 | The potential role of miRNAs in multiple myeloma therapy. *Expert Review of Hematology*, **2018**, 11, 793-803 | 3.8 | 20 |
| 127 | Multiple myeloma: monoclonal antibodies-based immunotherapeutic strategies and targeted radiotherapy. *European Journal of Cancer*, **2006**, 42, 1640-52 | 7.5 | 20 |
| 126 | Detection of microsatellite instability and loss of heterozygosity in serum DNA of small and non-small cell lung cancer patients: a tool for early diagnosis?. *Lung Cancer*, **2000**, 30, 211-4 | 5.9 | 20 |
| 125 | Transcriptional regulation of the mismatch repair gene hMLH1. *Gene*, **2001**, 275, 261-5 | 3.8 | 20 |
| 124 | Long non-coding RNA NEAT1 shows high expression unrelated to molecular features and clinical outcome in multiple myeloma. *Haematologica*, **2019**, 104, e72-e76 | 6.6 | 20 |
| 123 | Polymorphic Variants in NR1I3 and UGT2B7 Predict Taxane Neurotoxicity and Have Prognostic Relevance in Patients With Breast Cancer: A Case-Control Study. *Clinical Pharmacology and Therapeutics*, **2019**, 106, 422-431 | 6.1 | 19 |
| 122 | Phase I trial of thymidylate synthase poly-epitope peptide (TSPP) vaccine in advanced cancer patients. *Cancer Immunology, Immunotherapy*, **2015**, 64, 1159-73 | 7.4 | 19 |
| 121 | Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma. *Haematologica*, **2021**, 106, 185-195 | 6.6 | 19 |

| | | | |
|---|---|---|---|
| 120 | Challenging the current approaches to multiple myeloma-related bone disease: from bisphosphonates to target therapy. *Current Cancer Drug Targets*, **2009**, 9, 854-70 | 2.8 | 19 |
| 119 | BRCA1/2 genetic background-based therapeutic tailoring of human ovarian cancer: hope or reality?. *Journal of Ovarian Research*, **2009**, 2, 14 | 5.5 | 19 |
| 118 | Mass spectrometry-based identification of the tumor antigen UN1 as the transmembrane CD43 sialoglycoprotein. *Molecular and Cellular Proteomics*, **2011**, 10, M111.007898 | 7.6 | 19 |
| 117 | The IL-6 receptor super-antagonist Sant7 enhances antiproliferative and apoptotic effects induced by dexamethasone and zoledronic acid on multiple myeloma cells. *International Journal of Oncology* , **2002**, 21, 867-73 | 1 | 19 |
| 116 | Molecular profiling of multiple myeloma: from gene expression analysis to next-generation sequencing. *Expert Opinion on Biological Therapy*, **2013**, 13 Suppl 1, S55-68 | 5.4 | 18 |
| 115 | Second-line treatment of non small cell lung cancer by biweekly gemcitabine and docetaxel +/- granulocyte-macrophage colony stimulating factor and low dose aldesleukine. *Cancer Biology and Therapy*, **2009**, 8, 497-502 | 4.6 | 18 |
| 114 | The farnesyltransferase inhibitor R115777 (ZARNESTRA) enhances the pro-apoptotic activity of interferon-alpha through the inhibition of multiple survival pathways. *International Journal of Cancer*, **2007**, 121, 2317-30 | 7.5 | 18 |
| 113 | Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev). *Oncotarget*, **2017**, 8, 75904-75913 | 3.3 | 18 |
| 112 | Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients. *Future Oncology*, **2016**, 12, 2071-5 | 3.6 | 18 |
| 111 | A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine. *European Journal of Medicinal Chemistry*, **2019**, 183, 111715 | 6.8 | 17 |
| 110 | Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab. *Molecular and Clinical Oncology*, **2019**, 11, 81-90 | 1.6 | 17 |
| 109 | Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia. *Leukemia and Lymphoma*, **2015**, 56, 3150-8 | 1.9 | 17 |
| 108 | Novel therapeutic approaches based on the targeting of microenvironment-derived survival pathways in human cancer: experimental models and translational issues. *Current Pharmaceutical Design*, **2007**, 13, 487-96 | 3.3 | 17 |
| 107 | HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis. *Cells*, **2020**, 9, | 7.9 | 17 |
| 106 | Immunotherapy of colorectal cancer: new perspectives after a long path. *Immunotherapy*, **2016**, 8, 1281-1292 | 3.9 | 17 |
| 105 | Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents. *International Journal of Oncology*, **2005**, 26, 1257-63 | 1 | 17 |
| 104 | Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. *Journal of Hematology and Oncology*, **2019**, 12, 32 | 22.4 | 16 |
| 103 | Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade **2020**, 8, | | 16 |

| | | | |
|---|---|---|---|
| 102 | Alkyl phospholipid perifosine induces myeloid hyperplasia in a murine myeloma model. *Experimental Hematology*, **2007**, 35, 1038-46 | 3.1 | 16 |
| 101 | In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cells. *British Journal of Haematology*, **2006**, 134, 37-44 | 4.5 | 16 |
| 100 | Pharmacogenomics Biomarker Discovery and Validation for Translation in Clinical Practice. *Clinical and Translational Science*, **2021**, 14, 113-119 | 4.9 | 16 |
| 99 | Functional Analysis of microRNA in Multiple Myeloma. *Methods in Molecular Biology*, **2016**, 1375, 181-94 | 1.4 | 15 |
| 98 | Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients. *Journal of Thoracic Disease*, **2017**, 9, 3123-3131 | 2.6 | 15 |
| 97 | Development and validation of a bioanalytical method for quantification of LNA-i-miR-221, a 13-mer oligonucleotide, in rat plasma using LC-MS/MS. *Journal of Pharmaceutical and Biomedical Analysis*, **2018**, 150, 300-307 | 3.5 | 15 |
| 96 | The route to solve the interplay between inflammation, angiogenesis and anti-cancer immune response. *Cell Death and Disease*, **2016**, 7, e2299 | 9.8 | 15 |
| 95 | MYD88-independent growth and survival effects of Sp1 transactivation in Waldenstrom macroglobulinemia. *Blood*, **2014**, 123, 2673-81 | 2.2 | 15 |
| 94 | Analysis of miRNA, mRNA, and TF interactions through network-based methods. *Eurasip Journal on Bioinformatics and Systems Biology*, **2015**, 2015, 4 | | 15 |
| 93 | Antitumor therapeutic strategies based on the targeting of epidermal growth factor-induced survival pathways. *Current Drug Targets*, **2005**, 6, 289-300 | 3 | 15 |
| 92 | MicroRNAs in multiple myeloma and related bone disease. *Annals of Translational Medicine*, **2015**, 3, 334 | 3.2 | 15 |
| 91 | The Non-Coding RNA Landscape of Plasma Cell Dyscrasias. *Cancers*, **2020**, 12, | 6.6 | 14 |
| 90 | Non Coding RNAs: A New Avenue for the Self-Tailoring of Blood Cancer Treatment. *Current Drug Targets*, **2017**, 18, 35-55 | 3 | 14 |
| 89 | miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma. *Leukemia*, **2021**, 35, 823-834 | 10.7 | 14 |
| 88 | Automatic summarisation and annotation of microarray data. *Soft Computing*, **2011**, 15, 1505-1512 | 3.5 | 13 |
| 87 | An Anti-BCMA RNA Aptamer for miRNA Intracellular Delivery. *Molecular Therapy - Nucleic Acids*, **2019**, 18, 981-990 | 10.7 | 13 |
| 86 | Systematic review and meta-analysis on targeted therapy in advanced pancreatic cancer. *Pancreatology*, **2016**, 16, 249-58 | 3.8 | 12 |
| 85 | mTOR inhibitors, a new era for metastatic luminal HER2-negative breast cancer? A systematic review and a meta-analysis of randomized trials. *Oncotarget*, **2016**, 7, 27055-66 | 3.3 | 12 |

| | | | |
|---|---|---|---|
| 84 | OSAnalyzer: A Bioinformatics Tool for the Analysis of Gene Polymorphisms Enriched with Clinical Outcomes. *Microarrays (Basel, Switzerland)*, **2016**, 5, | | 12 |
| 83 | Immunomodulatory Activity of MicroRNAs: Potential Implications for Multiple Myeloma Treatment. *Current Cancer Drug Targets*, **2017**, 17, 819-838 | 2.8 | 11 |
| 82 | Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma). *Haematologica*, **2018**, 103, e473-e479 | 6.6 | 11 |
| 81 | Human mismatch-repair protein MutL homologue 1 (MLH1) interacts with Escherichia coli MutL and MutS in vivo and in vitro: a simple genetic system to assay MLH1 function. *Biochemical Journal*, **2003**, 371, 183-9 | 3.8 | 11 |
| 80 | UN1, a murine monoclonal antibody recognizing a novel human thymic antigen. *Tissue Antigens*, **1994**, 44, 73-82 | | 11 |
| 79 | GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up. *Frontiers in Oncology*, **2019**, 9, 1102 | 5.3 | 11 |
| 78 | Systemic inflammatory status predict the outcome of k-RAS WT metastatic colorectal cancer patients receiving the thymidylate synthase poly-epitope-peptide anticancer vaccine. *Oncotarget*, **2018**, 9, 20539-20554 | 3.3 | 11 |
| 77 | LncRNA NEAT1 in Paraspeckles: A Structural Scaffold for Cellular DNA Damage Response Systems?. *Non-coding RNA*, **2020**, 6, | 7.1 | 10 |
| 76 | Identification by differential display of transcripts regulated during hematopoietic differentiation. *Stem Cells*, **1998**, 16, 136-43 | 5.8 | 10 |
| 75 | Oxaliplatin (L-OHP) treatment of human myeloma cells induces in vitro growth inhibition and apoptotic cell death. *European Journal of Cancer*, **2002**, 38, 1141-7 | 7.5 | 10 |
| 74 | Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation. *Oncotarget*, **2016**, 7, 82741-82756 | 3.3 | 10 |
| 73 | Impact of Natural Dietary Agents on Multiple Myeloma Prevention and Treatment: Molecular Insights and Potential for Clinical Translation. *Current Medicinal Chemistry*, **2020**, 27, 187-215 | 4.3 | 10 |
| 72 | Hereditary nonpolyposis coloretal cancer: identification of novel germline mutations in two kindreds not fulfulling the Amsterdam criteria. Mutations in brief no. 203. Online. *Human Mutation*, **1998**, 12, 433 | 4.7 | 9 |
| 71 | Synthesis and preliminary evaluation of the anti-cancer activity on A549 lung cancer cells of a series of unsaturated disulfides. *MedChemComm*, **2019**, 10, 116-119 | 5 | 8 |
| 70 | Purification and characterization of a human sialoglycoprotein antigen expressed in immature thymocytes and fetal tissues. *Tissue Antigens*, **1998**, 51, 528-35 | | 8 |
| 69 | Targeting PI3K and RAD51 in Barrett's adenocarcinoma: impact on DNA damage checkpoints, expression profile and tumor growth. *Cancer Genomics and Proteomics*, **2012**, 9, 55-66 | 3.3 | 8 |
| 68 | Allometric Scaling Approaches for Predicting Human Pharmacokinetic of a Locked Nucleic Acid Oligonucleotide Targeting Cancer-Associated miR-221. *Cancers*, **2019**, 12, | 6.6 | 8 |
| 67 | The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis. *Critical Reviews in Oncology/Hematology*, **2018**, 125, 69-77 | 7 | 7 |

| | | | |
|---|---|---|---|
| 66 | Regulation of NF-kappa B nuclear activity in peripheral blood mononuclear cells: role of CD28 antigen. *Cellular Immunology*, **1994**, 156, 371-7 | 4.4 | 7 |
| 65 | A Phase I, Multi-Center, Dose Escalation Study of Atiprimod in Patients with Refractory or Relapsed Multiple Myeloma (MM).. *Blood*, **2005**, 106, 111-111 | 2.2 | 7 |
| 64 | Triggering of CD40 Antigen Inhibits Fludarabine-Induced Apoptosis in B Chronic Lymphocytic Leukemia Cells. *Blood*, **1998**, 92, 990-995 | 2.2 | 7 |
| 63 | Alternative Non-Homologous End-Joining: Error-Prone DNA Repair as Cancer's Achilles' Heel. *Cancers*, **2021**, 13, | 6.6 | 7 |
| 62 | DMET Genotyping: Tools for Biomarkers Discovery in the Era of Precision Medicine. *High-Throughput*, **2020**, 9, | 4.3 | 6 |
| 61 | A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it?. *Journal of Ovarian Research*, **2013**, 6, 10 | 5.5 | 6 |
| 60 | Partial purification and MALDI-TOF MS analysis of UN1, a tumor antigen membrane glycoprotein. *International Journal of Biological Macromolecules*, **2006**, 39, 122-6 | 7.9 | 6 |
| 59 | Pembrolizumab-Induced Psoriasis in Metastatic Melanoma: Activity and Safety of Apremilast, a Case Report. *Frontiers in Oncology*, **2020**, 10, 579445 | 5.3 | 6 |
| 58 | Differential expression of UN1, early thymocyte-associated sialoglycoprotein, in breast normal tissue, benign disease and carcinomas. *Anticancer Research*, **2002**, 22, 2333-40 | 2.3 | 6 |
| 57 | Error-prone DNA repair pathways as determinants of immunotherapy activity: an emerging scenario for cancer treatment. *International Journal of Cancer*, **2020**, 147, 2658-2668 | 7.5 | 5 |
| 56 | Dose-Finding Study and Pharmacokinetics Profile of the Novel 13-Mer Antisense miR-221 Inhibitor in Sprague-Dawley Rats. *Molecular Therapy - Nucleic Acids*, **2020**, 20, 73-85 | 10.7 | 5 |
| 55 | Enumeration of interleukin-10-positive B cells from peripheral blood of patients with chronic lymphocytic leukemia. *Leukemia and Lymphoma*, **2014**, 55, 1394-6 | 1.9 | 5 |
| 54 | Ink spot lentigo: singular clinical features in a case series of patients. *International Journal of Immunopathology and Pharmacology*, **2013**, 26, 953-5 | 3 | 5 |
| 53 | CD69 expression on primitive progenitor cells and hematopoietic malignancies. *Tissue Antigens*, **1996**, 48, 65-8 | | 5 |
| 52 | Alternative non-homologous end joining repair: a master regulator of genomic instability in cancer. *Precision Cancer Medicine*, **2019**, 2, 8-8 | 1 | 4 |
| 51 | CD36 is rapidly and transiently upregulated on phytohemagglutinin (PHA)-stimulated peripheral blood lymphocytes. Analysis by a new monoclonal antibody (UN7). *Tissue Antigens*, **1998**, 51, 671-5 | | 4 |
| 50 | Pegylated liposomal doxorubicin is active in Stewart-Treves syndrome. *Annals of Oncology*, **2007**, 18, 959-60 | 10.3 | 4 |
| 49 | Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents **2005**, 26, 1257 | | 4 |

| | | | |
|---|---|---|---|
| 48 | Defect of interleukin-2 production and T cell proliferation in atopic patients: restoring ability of the CD28-mediated activation pathway. *Cellular Immunology*, **1993**, 148, 455-63 | 4.4 | 4 |
| 47 | Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia **2021**, 9, | | 4 |
| 46 | Fetal ontogeny and tumor expression of the early thymic antigen UN1. *International Journal of Oncology*, **2002**, 20, 707-11 | 1 | 4 |
| 45 | Experimental treatment of multiple myeloma in the era of precision medicine. *Expert Review of Precision Medicine and Drug Development*, **2016**, 1, 37-51 | 1.6 | 3 |
| 44 | Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories. *Diagnostics*, **2019**, 9, | 3.8 | 3 |
| 43 | The IL-6 receptor super-antagonist Sant7 enhances antiproliferative and apoptotic effects induced by dexamethasone and zoledronic acid on multiple myeloma cells **2002**, 21, 867 | | 3 |
| 42 | Establishment of a Waldenstrom Macroglobulinemia Cell Line (BCWM.1) with Productive In Vivo Engraftment in SCID-hu Mice.. *Blood*, **2005**, 106, 979-979 | 2.2 | 3 |
| 41 | Aberrant Non-Homologous End Joining in Multiple Myeloma: A Role in Genomic Instability and As Potential Prognostic Marker.. *Blood*, **2012**, 120, 2932-2932 | 2.2 | 3 |
| 40 | Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis. *Life*, **2021**, 11, | 3 | 3 |
| 39 | Influence of the Fabrication Accuracy of Hot-Embossed PCL Scaffolds on Cell Growths. *Frontiers in Bioengineering and Biotechnology*, **2020**, 8, 84 | 5.8 | 3 |
| 38 | MMRF-CoMMpass Data Integration and Analysis for Identifying Prognostic Markers. *Lecture Notes in Computer Science*, **2020**, 564-571 | 0.9 | 3 |
| 37 | Identifying prognostic markers for multiple myeloma through integration and analysis of MMRF-CoMMpass data. *Journal of Computational Science*, **2021**, 51, 101346 | 3.4 | 3 |
| 36 | miR-22 Modulates Lenalidomide Activity by Counteracting MYC Addiction in Multiple Myeloma. *Cancers*, **2021**, 13, | 6.6 | 3 |
| 35 | Expression Pattern and Biological Significance of the lncRNA ST3GAL6-AS1 in Multiple Myeloma. *Cancers*, **2020**, 12, | 6.6 | 2 |
| 34 | The IASLC Lung Cancer Staging Project: revision proposal of pleural effusion and controlateral nodule staging. *Journal of Thoracic Oncology*, **2008**, 3, 317; author reply 317-8 | 8.9 | 2 |
| 33 | Risk Alleles for Multiple Myeloma Susceptibility in ADME Genes.. *Cells*, **2022**, 11, | 7.9 | 2 |
| 32 | Amifostine Inhibits Hematopoietic Progenitor Cell Apoptosis by Activating NF-B/Rel Transcription Factors. *Blood*, **1999**, 94, 4060-4066 | 2.2 | 2 |
| 31 | FlowCT for the analysis of large immunophenotypic datasets and biomarker discovery in cancer immunology. *Blood Advances*, **2021**, | 7.8 | 2 |

| | | | |
|---|---|---|---|
| 30 | Development and validation of bioanalytical methods for LNA-i-miR-221 quantification in human plasma and urine by LC-MS/MS. *Journal of Pharmaceutical and Biomedical Analysis*, **2020**, 188, 113451 | 3.5 | 1 |
| 29 | Challenges in Multiple Myeloma Chemoprevention: Potential Role of Natural, Synthetic and Endogenous Molecules **2016**, 37-60 | | 1 |
| 28 | Analysis of peripheral blood normal and malignant cells with the novel murine monoclonal antibody UN2. *Immunology Letters*, **1994**, 42, 55-62 | 4.1 | 1 |
| 27 | A novel monoclonal antibody recognizing human thymocytes and B-cell chronic lymphocytic leukemia cells. *Immunology Letters*, **1994**, 39, 137-46 | 4.1 | 1 |
| 26 | Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report.. *Therapeutic Advances in Chronic Disease*, **2022**, 13, 20406223211063024 | 4.9 | 1 |
| 25 | miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review.. *Molecular Therapy - Nucleic Acids*, **2022**, 27, 1191-1224 | 10.7 | 1 |
| 24 | Novel Hydroxamic Acid-Derived HDAC Inhibitor LBH589 Potently Activates Intrinsic and Extrinsic Apoptotic Pathways, and Induces Tubulin Hyperacetylation in Multiple Myeloma.. *Blood*, **2005**, 106, 1578-1578 | 2.2 | 1 |
| 23 | An Extension of the TIGR M4 Suite to Preprocess and Visualize Affymetrix Binary Files. *Lecture Notes in Computer Science*, **2009**, 265-274 | 0.9 | 1 |
| 22 | Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies. *ESMO Open*, **2022**, 7, 100459 | 6 | 1 |
| 21 | In Vitro Silencing of lncRNAs Using LNA GapmeRs. *Methods in Molecular Biology*, **2021**, 2348, 157-166 | 1.4 | 0 |
| 20 | Chromene Derivatives as Selective TERRA G-Quadruplex RNA Binders with Antiproliferative Properties. *Pharmaceuticals*, **2022**, 15, 548 | 5.2 | 0 |
| 19 | Multiple myeloma-related bone disease: state-of-art and next future treatments. *International Journal of Hematologic Oncology*, **2015**, 4, 33-47 | 1 | |
| 18 | Precision Oncology: Present Status and Perspectives. *Current Clinical Pathology*, **2017**, 7-26 | 0.1 | |
| 17 | Pharmacological Approaches for BRCA1/2 Related Breast and Ovarian Cancer: Preclinical Studies and Early Clinical Trials. *Current Womenks Health Reviews*, **2012**, 8, 104-110 | 0.2 | |
| 16 | Monoclonal Antibody Based Therapies in Human Multiple Myeloma. *Clinical Lymphoma and Myeloma*, **2009**, 9, S22-S23 | | |
| 15 | Molecular Rationales for Signal Transduction Therapy and Chemoprevention of BRCA1-Related Breast and Ovarian Tumours. *Current Signal Transduction Therapy*, **2007**, 2, 165-173 | 0.8 | |
| 14 | Detection of an antigenic marker expressed by peripheral blood monocytes and platelets by a new monoclonal antibody, UN8. *Tissue Antigens*, **1995**, 45, 288-91 | | |
| 13 | On the way of the new strategies aimed to improve the efficacy of PD-1/PD-L1 immune checkpoint blocking mAbs in small cell lung cancer. *Translational Lung Cancer Research*, **2020**, 9, 1712-1719 | 4.4 | |

| | | |
|---|---|---|
| 12 | Personalized Medicine. *UNIPA Springer Series*, **2021**, 391-399 | 0.1 |
| 11 | A Clinically Relevant SCID-hu in Vivo Model of Human Multiple Myeloma.. *Blood*, **2004**, 104, 2455-2455 | 2.2 |
| 10 | Atiprimod (N-N-diethl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) Inhibits Myeloma in Vivo.. *Blood*, **2004**, 104, 2401-2401 | 2.2 |
| 9 | Inhibition of Human Plasmacytoma Cell Growth by a Novel JAK Kinase Inhibitor.. *Blood*, **2004**, 104, 644-644 | 2.2 |
| 8 | Targeting Mitochondrial Factor Smac/DIABLO as Therapy for Multiple Myeloma (MM).. *Blood*, **2004**, 104, 764-764 | 2.2 |
| 7 | Elevated Apurinic/Apyrimidinic Endonuclease Activity Significantly Contributes to DNA Instability in Multiple Myeloma.. *Blood*, **2006**, 108, 2077-2077 | 2.2 |
| 6 | Modulation of Gene Expression Profile and In Vivo Anti-Myeloma Activity Induced by Valproic Acid, a Histone Deacytylase Inhibitor.. *Blood*, **2007**, 110, 4790-4790 | 2.2 |
| 5 | MiR-29b Counteracts Aberrant HDAC4 Expression and Enhances Vorinostat Activity in Multiple Myeloma. *Blood*, **2014**, 124, 2060-2060 | 2.2 |
| 4 | SCID-Synth-Hu: a Novel Multiple Myeloma Model for In Vivo Expansion of Primary Cells. *Blood*, **2010**, 116, 452-452 | 2.2 |
| 3 | The Expression Pattern of Small Nucleolar and Small Cajal Body-Specific RNAs Characterizes Distinct Molecular Subtypes of Multiple Myeloma. *Blood*, **2012**, 120, 3955-3955 | 2.2 |
| 2 | Integration of DNA Microarray with Clinical and Genomic Data.. *Methods in Molecular Biology*, **2022**, 2401, 239-248 | 1.4 |
| 1 | A Prognostic and Carboplatin Response Predictive Model in Ovarian Cancer: A Mono-Institutional Retrospective Study Based on Clinics and Pharmacogenomics. *Biomedicines*, **2022**, 10, 1210 | 4.8 |